Convallatoxin: a new P-glycoprotein substrate.

[1]  H. Wortelboer,et al.  Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3. , 2014, Molecular pharmaceutics.

[2]  Stephen G Aller,et al.  Refined structures of mouse P-glycoprotein , 2013, Protein science : a publication of the Protein Society.

[3]  D. Clarke,et al.  Drug Rescue Distinguishes between Different Structural Models of Human P-Glycoprotein , 2013, Biochemistry.

[4]  C. Cortinovis,et al.  Epidemiology of intoxication of domestic animals by plants in Europe. , 2013, Veterinary journal.

[5]  S. Zeng,et al.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management , 2013, Therapeutics and clinical risk management.

[6]  F. Russel,et al.  Interaction of digitalis-like compounds with p-glycoprotein. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[8]  F. Russel,et al.  Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. , 2012, Molecular pharmaceutics.

[9]  G. Coutance,et al.  Digitalis intoxication induced by an acute accidental poisoning by lily of the valley. , 2012, Circulation.

[10]  Christel A. S. Bergström,et al.  In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.

[11]  F. Russel,et al.  Cannabinoid Type 1 Receptor Antagonists Modulate Transport Activity of Multidrug Resistance-Associated Proteins MRP1, MRP2, MRP3, and MRP4 , 2011, Drug Metabolism and Disposition.

[12]  F. Fülöp,et al.  Comparison of 3 Assay Systems Using a Common Probe Substrate, Calcein AM, for Studying P-gp Using a Selected Set of Compounds , 2011, Journal of biomolecular screening.

[13]  Ingebrigt Sylte,et al.  Theoretical Biology and Medical Modelling Open Access Binding Site of Abc Transporter Homology Models Confirmed by Abcb1 Crystal Structure , 2022 .

[14]  D. Clarke,et al.  Identification of Residues in the Drug Translocation Pathway of the Human Multidrug Resistance P-glycoprotein by Arginine Mutagenesis* , 2009, The Journal of Biological Chemistry.

[15]  Ulf Norinder,et al.  Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.

[16]  S. Krim,et al.  Digoxin: current use and approach to toxicity. , 2008, The American journal of the medical sciences.

[17]  E. Krieger,et al.  Functional Role of Arginine 375 in Transmembrane Helix 6 of Multidrug Resistance Protein 4 (MRP4/ABCC4) , 2008, Molecular Pharmacology.

[18]  D. Clarke,et al.  Suppressor Mutations in the Transmembrane Segments of P-glycoprotein Promote Maturation of Processing Mutants and Disrupt a Subset of Drug-binding Sites* , 2007, Journal of Biological Chemistry.

[19]  D. Clarke,et al.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.

[20]  D. Kang,et al.  The positive inotropic effect of the aqueous extract of Convallaria keiskei in beating rabbit atria. , 2006, Life sciences.

[21]  Supratim Choudhuri,et al.  Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters , 2006, International journal of toxicology.

[22]  D. Clarke,et al.  Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. , 2006, The Biochemical journal.

[23]  S. Chong,et al.  A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. , 2005, International journal of pharmaceutics.

[24]  L. Angenot,et al.  Recent developments in the field of arrow and dart poisons. , 2005, Journal of ethnopharmacology.

[25]  D. Clarke,et al.  Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux , 2005, The Journal of Membrane Biology.

[26]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[27]  S. Chong,et al.  Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  E. Bamberg,et al.  Electrophysiological Analysis of the Mutated Na,K-ATPase Cation Binding Pocket* , 2003, Journal of Biological Chemistry.

[29]  J. Davie.  Inhibition of histone deacetylase activity by butyrate. , 2003, The Journal of nutrition.

[30]  Keld Kjeldsen,et al.  The Na, K-ATPase in the failing human heart. , 2003, Cardiovascular research.

[31]  D. Clarke,et al.  Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.

[32]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[33]  T. Sakaeda,et al.  MDR1 genotype-related pharmacokinetics and pharmacodynamics. , 2002, Biological & pharmaceutical bulletin.

[34]  G. Hooiveld,et al.  Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P‐glycoproteins , 2002, British journal of pharmacology.

[35]  D. Clarke,et al.  Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Fromm,et al.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  M. Fromm,et al.  P-glycoprotein-mediated transport of digitoxin, α-methyldigoxin and β-acetyldigoxin , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[39]  I. Buschmann,et al.  Digitoxin intoxication during concomitant use of amiodarone , 1998, European Journal of Clinical Pharmacology.

[40]  H. Kusuhara,et al.  P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.

[41]  G. Koren,et al.  The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. , 1997, The Journal of pharmacology and experimental therapeutics.

[42]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[43]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[44]  I. D. de Lannoy,et al.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. , 1992, Biochemical and biophysical research communications.

[45]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[46]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  H. Ozaki,et al.  Interaction of palytoxin and cardiac glycosides on erythrocyte membrane and (Na+ + K+) ATPase. , 1985, European journal of biochemistry.

[48]  F. Marcus.  Pharmacokinetic interactions between digoxin and other drugs. , 1985, Journal of the American College of Cardiology.

[49]  T. Smith.  Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. , 1985, Journal of the American College of Cardiology.

[50]  K. Nademanee,et al.  Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. , 1984, Journal of the American College of Cardiology.

[51]  G. Koren.  Digoxin-verapamil interaction--is it mutual? , 1983, Circulation.

[52]  G. Belz,et al.  Quinidine‐digoxin interaction: Cardiac efficacy of elevated serum digoxin concentration , 1982, Clinical pharmacology and therapeutics.

[53]  F. Lauterbach.  Comparison of intestinal penetration of cortisol and convallatoxin: demonstration of a transport mechanism for cardiotonic steroids. , 1968, Biochimica et biophysica acta.

[54]  D. Lorenz,et al.  [The native cardiac glycosides of Convallaria majalis. II. Pharmacology]. , 1958, Arzneimittel-Forschung.

[55]  P. Krajcsi,et al.  A novel screening strategy to identify ABCB1 substrates and inhibitors , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[56]  M. Castagna,et al.  Multidrug resistance P-glycoprotein expression in human fetal brain , 2006 .

[57]  M. Fromm,et al.  P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. , 2001, Naunyn-Schmiedeberg's archives of pharmacology.

[58]  Okumura,et al.  MDR 1 Genotype-Related Pharmacokinetics and Pharmacodynamics , 2022 .